Table 6 Antibody indices, CSF antibody concentrations and CSF PCR results for SARS-CoV-2, numerous other viruses, including herpes simplex virus (HSV), varicella zoster virus (VZV), cytomegalovirus (CMV), Epstein Barr virus (EBV), human herpes virus 6 (HHV6), measles virus (M), and rubella virus (R), and Borrelia burgdorferi (BB) in group I
Units | Total cohort | |
|---|---|---|
Positive antibody indices | ||
AI SARS-CoV-2, IgG | Samples | 2/20 (10%) |
Patients | 2/19 (10.5%) | |
AI SARS-CoV-2, IgM | Samples | 1/4 (25%) |
Patients | 1/4 (25%) | |
AI SARS-CoV-2, IgA | Samples | 1/4 (25%) |
Patients | 1/4 (25%) | |
AI HSV, IgG | Samples | 1/22 (4.5%) |
AI EBV, IgG | Samples | 0/4 (0%) |
AI CMV, IgG | Samples | 0/11 (0%) |
AI B. burgdorferi, IgG | Samples | 0/21 (0%) |
AI B. burgdorferi, IgM | Samples | 1/18 (5.6%) |
AI measles virus (M), IgG | Samples | 0/1 (0%) |
AI rubella virus (R), IgG | Samples | 0/1 (0%) |
AI varicella zoster virus (Z), IgG | Samples | 1/20 (5%) |
MRZ reaction (M + R, M + Z, R + Z, or M + R + Z) | Samples | 0/1 (0%) |
Patients | 0/1 (0%) | |
Elevated CSF antibody levels | ||
SARS-CoV-2, IgG | Samples | 20/29 (69%) |
Patients | 20/28 (71.4%) | |
SARS-CoV-2, IgM | Samples | 1/4 (25%) |
Patients | 1/4 (25%) | |
SARS-CoV-2, IgA | Samples | 1/4 (25%) |
Patients | 1/4 (25%) | |
Positive CSF PCR | ||
SARS-CoV-2 | Samples | 0/76 (0%) |
Patients | 0/75 (0%) | |
HSV | Samples | 0/59 (0%) |
VZV | Samples | 1/21 (4.8%) |
CMV | Samples | 0/20 (0%) |
EBV | Samples | 0/6 (0%) |
HHV6 | Samples | 0/5 (0%) |
Neurotropic viruses (panel) | Samples | 1/2 (50%) |